Celsus Therapeutics Plc (CLTX) 36.01 $CLTX
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015
M2 - Mon Nov 09, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttwz6m/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Allergan Plc - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lee's Pharmaceutical Holdings Limited - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Nanomerics Ltd - Neuroptis Biotech - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Rigel Pharmaceuticals, Inc. - Samjin Pharmaceutical Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - TearSolutions, LLC. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/tt...njunctivit
VRTX: 95.11 (+0.36), RIGL: 3.40 (-0.05), OCUL: 6.38 (+0.02), AGN: 235.96 (-1.80), SHPG: 192.37 (+3.87), MRK: 62.98 (+0.08), CLTX: 36.01 (+16.34)
Deerfield Leads Funding in Creation of Akari Therapeutics
PR Newswire - Mon Sep 21, 6:45AM CDT
Deerfield Management Company announced today that it will finance Akari Therapeutics, the new company created through the Celsus Therapeutics Plc (NASDAQ: CLTX) acquisition of Volution Immuno Pharmaceuticals SA. The transaction values the combined company on a fully diluted basis at approximately $150 million.
CLTX: 36.01 (+16.34)
Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce Completion of Acquisition and Formation of Complement C5 Inhibitor Company Akari Therapeutics Plc
GlobeNewswire - Fri Sep 18, 6:31AM CDT
Celsus Therapeutics Plc (NASDAQ:CLTX) and Volution Immuno Pharmaceuticals SA today announced that, following shareholder approval obtained at a general meeting of the shareholders of Celsus held on September 16, 2015, the previously announced acquisition by Celsus of Volution has closed. The combined company has changed its name to Akari Therapeutics, Plc and will trade on the NASDAQ Capital Market under the symbol "AKTX" beginning on September 21, 2015. Akari will focus on development and commercialization of life-transforming treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement C5, including paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS).
CLTX: 36.01 (+16.34)
4 Small Cap Stocks On The Verge Of A Breakout
ACCESSWIRE - Fri Aug 21, 7:05AM CDT
NEW YORK, NY / ACCESSWIRE / August 21, 2015 / UltimateStockAlerts.com is an exclusive NASDAQ/NYSE Investor Service that alerts undervalued and overlooked trade and investment opportunities. Today we will delve into four stocks that have been showcasing increased volatility combined with unusual volume over the past 24 hours, presenting increased bullish probability to witness potential gains.
T: 40.95 (-0.01), BTU: 2.07 (unch), ACI: 0.58 (-0.25), VGGL: 0.42 (unch), CLTX: 36.01 (+16.34)
Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce $75 Million Private Placement
Marketwired - Tue Aug 18, 6:16AM CDT
Celsus Therapeutics Plc (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that Celsus has entered into a securities purchase agreement for a private placement with a select group of investors, led by Deerfield, and including Venrock, Vivo Capital, Foresite Capital, New Enterprise Associates, QVT Financial, RA Capital Management and certain other institutional investors.
CLTX: 36.01 (+16.34)
Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce Agreement to Create Orphan Disease Company Focused on Complement C5 Inhibition
Marketwired - Mon Jul 13, 6:15AM CDT
Celsus Therapeutics (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that they have entered into a Definitive Exchange Agreement, pursuant to which privately-held Volution Immuno Pharmaceuticals will become a wholly-owned subsidiary of Celsus in an all-stock transaction. The combined company will focus on development and commercialization of life-transforming treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement C5, including paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS). Upon closing of the transaction, Celsus expects to be renamed Akari Therapeutics Plc.
CLTX: 36.01 (+16.34)
Allergic Conjunctivitis - Pipeline Review, H1 2015 Includes Late-stage and Discontinued Projects
M2 - Mon Jun 08, 6:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/js2p9k/allergic) has announced the addition of the "Allergic Conjunctivitis - Pipeline Review, H1 2015" report to their offering. . This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Conjunctivitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Alcon, Inc. - Allergan, Inc. - Celsus Therapeutics Plc - Eleven Biotherapeutics Inc. - Griffin Discoveries BV - Laila Pharmaceuticals Pvt. Ltd. - NicOx S.A. - Ocular Therapeutix, Inc. - Ohr Pharmaceutical Inc. - Oxagen Limited - Sun Pharma Advanced Research Company Ltd. - Xencor, Inc. For more information visit http://www.researchandmarkets.com/research/js2p9k/allergic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AGN: 235.96 (-1.80), OHRP: 2.72 (-0.05), CLTX: 36.01 (+16.34), XNCR: 20.35 (-1.08), OCUL: 6.38 (+0.02)
Global Dermatitis Pipeline Review 2015
M2 - Mon Apr 27, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7sjwj3/dermatitis) has announced the addition of the "Dermatitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dermatitis Overview - Therapeutics Development - Dermatitis - Therapeutics under Development by Companies - Dermatitis - Therapeutics under Investigation by Universities/Institutes - Dermatitis - Pipeline Products Glance - Dermatitis - Products under Development by Companies - Dermatitis - Products under Investigation by Universities/Institutes - Dermatitis - Companies Involved in Therapeutics Development - Dermatitis - Therapeutics Assessment - Drug Profiles - Dermatitis - Recent Pipeline Updates - Dermatitis - Dormant Projects - Dermatitis - Discontinued Products - Dermatitis - Product Development Milestones - Appendix Companies Mentioned - Partial List - AlbireoPharma - Amorepacific Corporation - Anacor Pharmaceuticals, Inc. - AnaMar AB - AnaptysBio, Inc. - AnGes MG, Inc. - Aquinox Pharmaceuticals Inc. - arGEN-X BV - Biomar Microbial Technologies - Blueberry Therapeutics Ltd - Brickell Biotech, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Celsus Therapeutics Plc - ChemoCentryx, Inc. - China Biologic Products, Inc. - ChironWells GmbH - Chugai Pharmaceutical Co., Ltd. - Circassia Pharmaceuticals plc - Convoy Therapeutics, Inc. - Creabilis SA - Daiichi Sankyo Company, Limited - Dermira Inc. - Eisai Co., Ltd. - EpiPharm AG - F. Hoffmann-La Roche Ltd. - FAES Farma SA - Foamix Pharmaceuticals Ltd. - Fountain Biopharma Inc. - GlaxoSmithKline plc For more information visit http://www.researchandmarkets.com/research/7sjwj3/dermatitis
AQXP: 12.14 (-0.10), FOMX: 8.73 (+0.06), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41), CBPO: 112.13 (+1.56), DERM: 32.52 (+0.30), CCXI: 4.22 (-1.07), ANAC: 99.06 (-0.14), CLTX: 36.01 (+16.34), CELGZ: 1.18 (+0.05)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 7.01 (+0.17), FOMX: 8.73 (+0.06), PVCT: 0.13 (unch), JNJ: 119.32 (+0.24), DERM: 32.52 (+0.30), ANAC: 99.06 (-0.14), XNCR: 20.35 (-1.08), REGN: 388.64 (-4.76), AQXP: 12.14 (-0.10), BMY: 56.35 (-0.41), GSK: 44.26 (+1.28), VRX.TO: 37.34 (-0.75), CBPO: 112.13 (+1.56), MRK: 62.98 (+0.08), CCXI: 4.22 (-1.07), CLTX: 36.01 (+16.34), CELGZ: 1.18 (+0.05), NVS: 79.38 (+1.11)
Boston Scientific and Fossil are big market movers
AP - Wed Feb 18, 3:31PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
JACK: 101.53 (+1.83), KNDI: 6.22 (+0.06), FOSL: 28.13 (-0.02), VDSI: 18.86 (+0.49), GT: 29.73 (+0.53), ANGI: 10.35 (+0.15), GOOGL: 796.87 (+5.47), CLTX: 36.01 (+16.34), GOOG: 771.46 (+2.68), YNDX: 22.39 (+0.20)
Celsus Plunges on Dismal Dermatology Drug Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 2:02PM CST
Shares of Celsus Therapeutics (CLTX) fell significantly after the company reported dismal results from a phase II trial on lead pipeline candidate, MRX-6 cream.
LCI: 31.79 (-1.58), SLXP: 172.96 (+0.15), SCMP: 11.10 (unch), CLTX: 36.01 (+16.34)
Celsus Therapeutics Announces That the Phase II Trial of MRX-6 Cream 2% in Pediatric Atopic Dermatitis Did Not Reach Primary Endpoint
GlobeNewswire - Tue Feb 17, 6:19AM CST
Celsus Therapeutics (Nasdaq:CLTX), an emerging growth, development-stage biopharmaceutical company, announced today the results from C012013, a Phase II, double-blind, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of MRX-6 cream 2% in a pediatric population with mild to moderate atopic dermatitis. MRX-6 cream did not demonstrate a difference in mean change from baseline to Day 28 in the Investigator's Global Assessment (IGA):
CLTX: 36.01 (+16.34)
Celsus Therapeutics concludes pediatric atopic dermatitis MRX-6 cream 2% enrollment trial
M2 - Wed Jan 14, 6:59AM CST
Biopharmaceutical company Celsus Therapeutics (NasdaqCM:CLTX) disclosed on Tuesday the completion of the enrollment in C012013 trial to evaluate MRX-6 cream 2% in a pediatric atopic dermatitis.
CLTX: 36.01 (+16.34)
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015
M2 - Mon Nov 09, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttwz6m/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Allergan Plc - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lee's Pharmaceutical Holdings Limited - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Nanomerics Ltd - Neuroptis Biotech - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Rigel Pharmaceuticals, Inc. - Samjin Pharmaceutical Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - TearSolutions, LLC. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/tt...njunctivit
VRTX: 95.11 (+0.36), RIGL: 3.40 (-0.05), OCUL: 6.38 (+0.02), AGN: 235.96 (-1.80), SHPG: 192.37 (+3.87), MRK: 62.98 (+0.08), CLTX: 36.01 (+16.34)
Deerfield Leads Funding in Creation of Akari Therapeutics
PR Newswire - Mon Sep 21, 6:45AM CDT
Deerfield Management Company announced today that it will finance Akari Therapeutics, the new company created through the Celsus Therapeutics Plc (NASDAQ: CLTX) acquisition of Volution Immuno Pharmaceuticals SA. The transaction values the combined company on a fully diluted basis at approximately $150 million.
CLTX: 36.01 (+16.34)
Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce Completion of Acquisition and Formation of Complement C5 Inhibitor Company Akari Therapeutics Plc
GlobeNewswire - Fri Sep 18, 6:31AM CDT
Celsus Therapeutics Plc (NASDAQ:CLTX) and Volution Immuno Pharmaceuticals SA today announced that, following shareholder approval obtained at a general meeting of the shareholders of Celsus held on September 16, 2015, the previously announced acquisition by Celsus of Volution has closed. The combined company has changed its name to Akari Therapeutics, Plc and will trade on the NASDAQ Capital Market under the symbol "AKTX" beginning on September 21, 2015. Akari will focus on development and commercialization of life-transforming treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement C5, including paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS).
CLTX: 36.01 (+16.34)
4 Small Cap Stocks On The Verge Of A Breakout
ACCESSWIRE - Fri Aug 21, 7:05AM CDT
NEW YORK, NY / ACCESSWIRE / August 21, 2015 / UltimateStockAlerts.com is an exclusive NASDAQ/NYSE Investor Service that alerts undervalued and overlooked trade and investment opportunities. Today we will delve into four stocks that have been showcasing increased volatility combined with unusual volume over the past 24 hours, presenting increased bullish probability to witness potential gains.
T: 40.95 (-0.01), BTU: 2.07 (unch), ACI: 0.58 (-0.25), VGGL: 0.42 (unch), CLTX: 36.01 (+16.34)
Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce $75 Million Private Placement
Marketwired - Tue Aug 18, 6:16AM CDT
Celsus Therapeutics Plc (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that Celsus has entered into a securities purchase agreement for a private placement with a select group of investors, led by Deerfield, and including Venrock, Vivo Capital, Foresite Capital, New Enterprise Associates, QVT Financial, RA Capital Management and certain other institutional investors.
CLTX: 36.01 (+16.34)
Celsus Therapeutics and Volution Immuno Pharmaceuticals Announce Agreement to Create Orphan Disease Company Focused on Complement C5 Inhibition
Marketwired - Mon Jul 13, 6:15AM CDT
Celsus Therapeutics (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that they have entered into a Definitive Exchange Agreement, pursuant to which privately-held Volution Immuno Pharmaceuticals will become a wholly-owned subsidiary of Celsus in an all-stock transaction. The combined company will focus on development and commercialization of life-transforming treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement C5, including paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS). Upon closing of the transaction, Celsus expects to be renamed Akari Therapeutics Plc.
CLTX: 36.01 (+16.34)
Allergic Conjunctivitis - Pipeline Review, H1 2015 Includes Late-stage and Discontinued Projects
M2 - Mon Jun 08, 6:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/js2p9k/allergic) has announced the addition of the "Allergic Conjunctivitis - Pipeline Review, H1 2015" report to their offering. . This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Conjunctivitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type Companies Mentioned: - Alcon, Inc. - Allergan, Inc. - Celsus Therapeutics Plc - Eleven Biotherapeutics Inc. - Griffin Discoveries BV - Laila Pharmaceuticals Pvt. Ltd. - NicOx S.A. - Ocular Therapeutix, Inc. - Ohr Pharmaceutical Inc. - Oxagen Limited - Sun Pharma Advanced Research Company Ltd. - Xencor, Inc. For more information visit http://www.researchandmarkets.com/research/js2p9k/allergic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AGN: 235.96 (-1.80), OHRP: 2.72 (-0.05), CLTX: 36.01 (+16.34), XNCR: 20.35 (-1.08), OCUL: 6.38 (+0.02)
Global Dermatitis Pipeline Review 2015
M2 - Mon Apr 27, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7sjwj3/dermatitis) has announced the addition of the "Dermatitis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dermatitis Overview - Therapeutics Development - Dermatitis - Therapeutics under Development by Companies - Dermatitis - Therapeutics under Investigation by Universities/Institutes - Dermatitis - Pipeline Products Glance - Dermatitis - Products under Development by Companies - Dermatitis - Products under Investigation by Universities/Institutes - Dermatitis - Companies Involved in Therapeutics Development - Dermatitis - Therapeutics Assessment - Drug Profiles - Dermatitis - Recent Pipeline Updates - Dermatitis - Dormant Projects - Dermatitis - Discontinued Products - Dermatitis - Product Development Milestones - Appendix Companies Mentioned - Partial List - AlbireoPharma - Amorepacific Corporation - Anacor Pharmaceuticals, Inc. - AnaMar AB - AnaptysBio, Inc. - AnGes MG, Inc. - Aquinox Pharmaceuticals Inc. - arGEN-X BV - Biomar Microbial Technologies - Blueberry Therapeutics Ltd - Brickell Biotech, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Celsus Therapeutics Plc - ChemoCentryx, Inc. - China Biologic Products, Inc. - ChironWells GmbH - Chugai Pharmaceutical Co., Ltd. - Circassia Pharmaceuticals plc - Convoy Therapeutics, Inc. - Creabilis SA - Daiichi Sankyo Company, Limited - Dermira Inc. - Eisai Co., Ltd. - EpiPharm AG - F. Hoffmann-La Roche Ltd. - FAES Farma SA - Foamix Pharmaceuticals Ltd. - Fountain Biopharma Inc. - GlaxoSmithKline plc For more information visit http://www.researchandmarkets.com/research/7sjwj3/dermatitis
AQXP: 12.14 (-0.10), FOMX: 8.73 (+0.06), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41), CBPO: 112.13 (+1.56), DERM: 32.52 (+0.30), CCXI: 4.22 (-1.07), ANAC: 99.06 (-0.14), CLTX: 36.01 (+16.34), CELGZ: 1.18 (+0.05)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 7.01 (+0.17), FOMX: 8.73 (+0.06), PVCT: 0.13 (unch), JNJ: 119.32 (+0.24), DERM: 32.52 (+0.30), ANAC: 99.06 (-0.14), XNCR: 20.35 (-1.08), REGN: 388.64 (-4.76), AQXP: 12.14 (-0.10), BMY: 56.35 (-0.41), GSK: 44.26 (+1.28), VRX.TO: 37.34 (-0.75), CBPO: 112.13 (+1.56), MRK: 62.98 (+0.08), CCXI: 4.22 (-1.07), CLTX: 36.01 (+16.34), CELGZ: 1.18 (+0.05), NVS: 79.38 (+1.11)
Boston Scientific and Fossil are big market movers
AP - Wed Feb 18, 3:31PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
JACK: 101.53 (+1.83), KNDI: 6.22 (+0.06), FOSL: 28.13 (-0.02), VDSI: 18.86 (+0.49), GT: 29.73 (+0.53), ANGI: 10.35 (+0.15), GOOGL: 796.87 (+5.47), CLTX: 36.01 (+16.34), GOOG: 771.46 (+2.68), YNDX: 22.39 (+0.20)
Celsus Plunges on Dismal Dermatology Drug Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 2:02PM CST
Shares of Celsus Therapeutics (CLTX) fell significantly after the company reported dismal results from a phase II trial on lead pipeline candidate, MRX-6 cream.
LCI: 31.79 (-1.58), SLXP: 172.96 (+0.15), SCMP: 11.10 (unch), CLTX: 36.01 (+16.34)
Celsus Therapeutics Announces That the Phase II Trial of MRX-6 Cream 2% in Pediatric Atopic Dermatitis Did Not Reach Primary Endpoint
GlobeNewswire - Tue Feb 17, 6:19AM CST
Celsus Therapeutics (Nasdaq:CLTX), an emerging growth, development-stage biopharmaceutical company, announced today the results from C012013, a Phase II, double-blind, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of MRX-6 cream 2% in a pediatric population with mild to moderate atopic dermatitis. MRX-6 cream did not demonstrate a difference in mean change from baseline to Day 28 in the Investigator's Global Assessment (IGA):
CLTX: 36.01 (+16.34)
Celsus Therapeutics concludes pediatric atopic dermatitis MRX-6 cream 2% enrollment trial
M2 - Wed Jan 14, 6:59AM CST
Biopharmaceutical company Celsus Therapeutics (NasdaqCM:CLTX) disclosed on Tuesday the completion of the enrollment in C012013 trial to evaluate MRX-6 cream 2% in a pediatric atopic dermatitis.
CLTX: 36.01 (+16.34)
